Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020
January 07 2020 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional therapeutics, today announced
that management will present a corporate overview and updated
clinical development plans for its lead candidates ZW25 and ZW49 at
the upcoming 38th Annual J.P. Morgan Healthcare Conference on
Monday, January 13, 2020 at 3:30 p.m. PT.
The presentation will be webcast live and available for replay
on Zymeworks’ website
at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody
currently in Phase 2 clinical development. Zymeworks’ second
clinical candidate, ZW49, is a bispecific antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of ZW25 with Zymeworks’ proprietary
ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep
preclinical pipeline in immuno-oncology and other therapeutic
areas. In addition, its therapeutic platforms are being leveraged
through strategic partnerships with nine biopharmaceutical
companies. For more information, visit www.zymeworks.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200107005169/en/
Investor Inquiries:Ryan Dercho, Ph.D.(604)
678-1388ir@zymeworks.com
Tiffany Tolmie(604) 678-1388ir@zymeworks.com
Media Inquiries:Kavita Shah, Ph.D.(604)
678-1388media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024